A1LN34:BVMF
Alnylam Pharmaceuticals Inc Bdr
R$59,40
0,00%
(0,00) 1D
15 Okt., 21:31:36 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1LN34...
Open
R$58,26
High
R$59,40
Low
R$58,26
Mkt. cap
31,32 mjd
Avg. vol.
440,00
Volume
0,00
52-wk high
R$132,40
52-wk low
R$50,25
Shares outstanding
133,81 m
No. of employees
2 k
Open
R$58,26
High
R$59,40
Low
R$58,26
Mkt. cap
31,32 mjd
Avg. vol.
440,00
Volume
0,00
52-wk high
R$132,40
52-wk low
R$50,25
Shares outstanding
133,81 m
No. of employees
2 k
News stories
From web sources and news partners
ad-hoc-news.de
·
9 uur gelede
Citigroup cuts target to USD 320 for Alnylam Pharmaceuticals stock
Alnylam
·
16 uur gelede
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
BioSpace
·
2 dae gelede
Alnylam bulls and bears fight it out after business-shaking guidance cut
The Globe and Mail
·
2 weke gelede
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals Inc Bdr